Advertisement

Endocrine

pp 1–7 | Cite as

Unusual metastases from differentiated thyroid carcinoma: analysis of 36 cases

  • Anabela ZuninoEmail author
  • Fabián Pitoia
  • Eduardo Faure
  • Adriana Reyes
  • Mónica Sala
  • Rosana Sklate
  • Verónica Ilera
  • Inés Califano
  • on behalf of the Thyroid Department of Sociedad Argentina de Endocrinología y Metabolismo
Original Article
  • 73 Downloads

Abstract

Purpose

Metastases of differentiated thyroid cancer (DTC) in sites different from lungs and bone are unusual (UM); their impact in management and prognosis remains unknown. Our aim was to evaluate the prevalence of UM, to describe their characteristics and to analyze their impact in disease outcome and mortality.

Methods

We retrospectively reviewed the file records from 8 different centers. Those patients with DTC and UM were included. UM were diagnosed by: (i) biopsy/cytology and/or (ii) radioiodine (RAI) uptake associated to elevated thyroglobulin (Tg) levels and/or c) presence of one or more structural lesion/s with 18-FDG uptake in the PET/CT scan and elevated Tg levels.

Results

Thirty-six (0.9%) out of a total of 3982 DTC patients were diagnosed with UM; 75% had papillary histology. The most frequent localization was central nervous system (CNS, 31%). UM were metachronous in 75%, symptomatic in 55.6% and fulfilled RAI-refractoriness criteria in 77.8% of cases. Metastatic lesions in lung/bone and/or locoregional disease were present in 34 cases (94.4%). Diagnosis of UM changed the therapeutic approach in 72.2% of patients. After a median follow up of 13 months, 21 (58.3%) patients died from DTC related causes. In 8 of them CNS progression was the immediate cause of death.

Conclusions

Prevalence of UM was low; they were frequently metachronic and RAI-refractory. Although UM were found in patients with widespread disease, their diagnosis usually led to changes in therapy. UM were associated with poor prognosis and high frequency of disease-specific mortality.

Keywords

Thyroid carcinoma Distant metastases Unusual metastases Advanced thyroid cancer Radioiodine refractory 

Notes

Acknowledgements

We thank the members of the Thyroid Department of Sociedad Argentina de Endocrinología y Metabolismo: Abalovich Marcos, Abelleira Erika, Alcaraz Graciela, Bielski Laila, Brenta Gabriela, Cabezón Carmen, Calabrese María, Castro Jozami Lorena, Cavallo Andrea, Corino Mirta, Deutsch Susana, Frascaroli Genoveva, Gauna Alicia, Guerra Jorgelina, Gutierrez Silvia, Iorcansky Sonia, Löwenstein Alicia, Martínez Maria, Moldes Sofia, Negueruela Maria, Oneto Adriana, Orlandi Ana, Parisi Carina, Rosemblit Cinthia, Russo Picasso Maria, Saban Melina, Sartorio Gerardo, Schnitman Marta, Silva Croome Maria, Storani Maria, Vazquez Adriana, Zund Santiago.

Compliance with ethical standards

Conflict of interest

F.P. is medical advisor, speaker, and Steering Committee Bayer and Consultancy/Speaker bureau for Sanofi and Raffo Laboratories. E.F. is medical advisor and speaker for Sanofi and Speaker for Bayer and Raffo Laboratories. I.C. is medical advisor and speaker for Sanofi and Speaker for Bayer and Raffo Laboratories. The remaining authors declare that they have no conflict of interest.

Ethical approval

This article does not contain any studies with animals performed by any of the authors. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments. As this was a retrospective non interventional study, written consent was deemed unnecessary.

References

  1. 1.
    T.P. Links, Life expectancy in differentiated thyroid cancer: a novel approach to survival analysis. Endocr. Relat. Cancer 12(2), 273–280 (2005)CrossRefGoogle Scholar
  2. 2.
    B.R. Haugen, 2015 American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association Guidelines Task Force on thyroid nodules and differentiated thyroid cancer. Thyroid 26(1), 1–133 (2016)CrossRefGoogle Scholar
  3. 3.
    J.M. Mihailovic, Metastatic differentiated thyroid carcinoma: clinical management and outcome of disease in patients with initial and late distant metastases. Nucl. Med Commun. 30(7), 558–564 (2009)CrossRefGoogle Scholar
  4. 4.
    A. Leite, 2017 Deaths related to differentiated thyroid cancer: a rare but real event. Arch. Endocrinol. Metab. 61(3), 222–227 (2017)CrossRefGoogle Scholar
  5. 5.
    Y. Kitamura, Immediate causes of death in thyroid carcinoma: clinicopathological analysis of 161 fatal cases. J. Clin. Endocrinol. Metab. 84, 4043–4049 (1999)CrossRefGoogle Scholar
  6. 6.
    I.J. Nixon, The impact of distant metastases at presentation on prognosis in patients with differentiated thyroid carcinoma of the thyroid gland. Thyroid 22(9), 884–889 (2012)CrossRefGoogle Scholar
  7. 7.
    H. Kim, Prognosis of differentiated thyroid carcinoma with initial distant metastasis: a multicenter study in Korea. Endocrinol. Metab. 33, 287–295 (2018)CrossRefGoogle Scholar
  8. 8.
    A. Madani, Rare metastases of well-differentiated thyroid cancers: a systematic review. Ann. Surg. Oncol. 22, 460–466 (2015)CrossRefGoogle Scholar
  9. 9.
    E. Farina, Unusual thyroid carcinoma metastases: a case series and literature review. Endocr. Pathol. 27(1), 55–64 (2016)CrossRefGoogle Scholar
  10. 10.
    M.B. Amin, S. Edge, F. Greene, D.R. Byrd, R.K. Brookland, M.K. Washington, J.E. Gershenwald, C.C. Compton, K.R. Hess, D.C. Sullivan, J.M. Jessup, J.D. Brierley, L.E. Gaspar, R.L. Schilsky, C.M. Balch, D.P. Winchester, E.A. Asare, M. Madera, D.M. Gress, L.R. Meyer AJCC Cancer Staging Manual, 8th edn. (Springer, New York, 2017)Google Scholar
  11. 11.
    F. Pitoia, Consenso intersocietario sobre tratamiento y seguimiento de pacientes con cáncer diferenciado de tiroides. Inter Society Consensus for the Management of Patients with Differentiated Thyroid Cancer. Rev. Arg. Endocrinol. Metab. 51(2), 85–118 (2014)Google Scholar
  12. 12.
    M. Schlumberger, Definition and management of radioactive iodine- refractory differentiated thyroid cancer. Lancet Diabetes Endocrinol. 2(5), 356–358 (2014)CrossRefGoogle Scholar
  13. 13.
    D. Hirsch, 2017 Long term outcomes and prognostic factors in patients with differentiated thyroid cancer and distant metastases. Endocr. Pr. 23(10), 1193–1200 (2017)CrossRefGoogle Scholar
  14. 14.
    C. Durante, Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J. Clin. Endocrinol. Metab. 91(8), 2892–2899 (2006)CrossRefGoogle Scholar
  15. 15.
    R. Elisei, Are the clinical and pathological features of differentiated thyroid carcinoma really changed over the last 35 years? Study on 4187 patients from a single Italian institution to answer this question. J. Clin. Endocrinol. Metab. 95, 1516–1527 (2010)CrossRefGoogle Scholar
  16. 16.
    G. Grani, Follicular thyroid cancer and Hürthle cell carcinoma: challenges in diagnosis, treatment and clinical management. Lancet Diabetes Endocrinol. 6(6), 500–514 (2018)CrossRefGoogle Scholar
  17. 17.
    B. Henriques de Figueiredo, Brain metastases from thyroid carcinoma: a retrospective study of 21 cases. Thyroid 24(2), 270–276 (2014)CrossRefGoogle Scholar
  18. 18.
    H.S. Lee, Clinical characteristics and follow-up of intracranial metastases from thyroid cancer. Acta Neurochir. (Wien.) 157(12), 2185–2194 (2015)CrossRefGoogle Scholar
  19. 19.
    J. Simões-Pereira, Clinical outcomes of a cohort of patients with central nervous system metastases from thyroid cancer. Endocr. Connect. 5(6), 82–88 (2016)CrossRefGoogle Scholar
  20. 20.
    I. Slutzky-Shraga, Clinical characteristics and disease outcome of patients with non-medullary thyroid cancer and brain metastases. Oncol. Lett. 15(1), 672–676 (2018)Google Scholar
  21. 21.
    National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN guidelines). Thyroid carcinoma (version 3. 18) https://www.nccn.org/store/login/login.aspx?ReturnURL=https://www.nccn.org/professionals/physician_gls/pdf/thyroid.pdf. Accessed 8 March 2019.
  22. 22.
    R.J. Robbins, Real-time prognosis for metastatic thyroid carcinoma based on 2 –18 F fluoro-2-deoxy-D-glucose-positron emission tomography scanning. J. Clin. Endocrinol. Metab. 91(2), 498–505 (2006)CrossRefGoogle Scholar
  23. 23.
    L.Y. Wang, Multi-organ distant metastases confer worse disease-specific survival in differentiated thyroid cancer. Thyroid 24(11), 1594–1599 (2014)CrossRefGoogle Scholar
  24. 24.
    A. Sabet, Distinguishing synchronous from metachronous manifestation of distant metastases: a prognostic feature in differentiated thyroid carcinoma. Eur. J. Nucl. Med Mol. Imaging 44(2), 190–195 (2017)CrossRefGoogle Scholar
  25. 25.
    J. Lee, Differentiated thyroid carcinoma presenting with distant metastasis at initial diagnosis. Clinical outcomes and prognostic factors. Ann. Surg. 251(1), 114–119 (2010)CrossRefGoogle Scholar
  26. 26.
    F. Vaisman, A new appraisal of radiodine refractory thyroid cancer. Endocr. Relat. Cancer 22(6), R301–R310 (2015)CrossRefGoogle Scholar
  27. 27.
    F. Pitoia, Long-term survival and low effective cumulative dose of radioiodine doses to achieve remission in patients with 131Iodine-avid lung metastases from differentiated thyroid cancer. Clin. Nucl. Med. 39(9), 784–790 (2014)CrossRefGoogle Scholar
  28. 28.
    I. Califano, Outcomes of patients with bone metastases from differentiated thyroid cancer. Arch. Endocrinol. Metab. 62(1), 14–20 (2018)CrossRefGoogle Scholar
  29. 29.
    M.A. Tunio, Pancreas as delayed site of metastases from papillary thyroid carcinoma. Case Rep. Gastrointest. Med. 2013(386263), 1–4 (2013).  https://doi.org/10.1155/2013/386263
  30. 30.
    S. Ginzburg, Papillary thyroid carcinoma metastases presenting as ipsilateral adrenal mass and renal cyst. Urol. Case Rep. 3(6), 221–222 (2015)CrossRefGoogle Scholar
  31. 31.
    M.A. Tunio, Skeletal-muscle metastasis as an initial presentation of follicular thyroid carcinoma: a case report and a review of the literature. Case Rep. Endocrinol. 2013(192573), 1–4 (2013).  https://doi.org/10.1155/2013/192573
  32. 32.
    C. Brient, Differentiated thyroid cancer with liver metastases: lessons learned from managing a series of 14 patients. Int Surg. 100(3), 490–496 (2015)CrossRefGoogle Scholar
  33. 33.
    B. Robinson, Characterization of tumor size changes over time from the phase 3 study in lenvatinib on thyroid cancer. J. Clin. Endocrinol. Metab. 101(11), 4103–4109 (2016)CrossRefGoogle Scholar
  34. 34.
    M.E. Cabanillas, Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: the MD Anderson experience. J. Clin. Endocrinol. Metab. 95(6), 2588–2595 (2010)CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Thyroid Department of Sociedad Argentina de Endocrinología y MetabolismoCiudad Autónoma de Buenos AiresArgentina

Personalised recommendations